Politics, Pricing

‘We can’t’: Jeff Leiden stands his ground as MPs grill Vertex on pricing disagreement with NHS


Jeff Leiden began his testimony in front of the UK Parliament’s Health and Social Care Committee with a note that as a medical student, he’s spent three months in London’s Queen Square Hospital. That first-hand knowledge of the NHS, however, has not helped ease tensions with the single payer system for the past few years over the reimbursement of Orkambi. Nor did it bring him any closer to the politicians who invited him under the spotlight on Thursday.

In an hourlong back and forth between the Vertex CEO, his chief commercial officer and several MPs where accusations and frustrations were lurking just under a thin veil of British politeness, the two sides dug into the company’s business model, executive compensation, the role of public and philanthropic dollars in developing new cystic fibrosis drugs, as well as moral and political implications of the whole discussion.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->